Levels of Circulating Cell-Free Nuclear and Mitochondrial DNA in Benign and Malignant Ovarian Tumors
The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To analyze the levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in patients with benign and malignant ovarian tumors using a gold-standard assay and to investigate whether quantitative alterations of the circulating cell-free species have values in the management of the patients. METHODS: One hundred four patients were recruited for this study. We developed a quantitative, multiplex polymerase chain reaction to measure the levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in serum and plasma of patients with epithelial ovarian cancer, benign epithelial ovarian tumors, or endometriosis. The levels of the circulating cell-free DNA were compared with those of a healthy, age-matched control group. RESULTS: The patients with epithelial ovarian cancer had significantly higher amounts of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in plasma compared with the healthy control group (mean of nuclear DNA 10,723/2,591 and mean of mitochondrial DNA 4,918,978/2,294,264, P=.009 and 0.022, respectively) and with the other group with benign ovarian diseases (mean of nuclear DNA 10,723/2,965 and mean of mitochondrial DNA 4,918,978/1,597,551, P=.027 and 0.002, respectively). However, no relationship between levels of the circulating cell-free DNA and the pathological parameters as well as CA 125 measurement in patients with epithelial ovarian cancer was found. A significant difference between the epithelial ovarian cancer and endometriosis group was found in circulating cell-free mitochondrial DNA but not in circulating cell-free nuclear DNA (mean of mitochondrial DNA 4,918,978/2,273,988 and mean of nuclear DNA 10,723/3,291, P=.013 and 0.105, respectively). CONCLUSION: Elevated levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in epithelial ovarian cancer may have diagnostic value. Our finding suggests that the circulating molecules might be potential biomarkers in the disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, circulating mtDNA has been identified in patients with ovarian (Zachariah et al., 2008), testicular (Ellinger et al., 2009), prostate (Ellinger et al., 2009), and lung cancer (Hou et al., 2013).”
From Cytoplasmic DNA: sources, sensing, and role in aging and disease (2021) · cites this paper as Zachariah et al., 2008
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Heid, C. A., Stevens, J., Livak, K. J., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,174
Lo, Y. M. D., Tein, M. S. C., Lau, T. K., Haines, C. J., Leung, T. N., Poon, P. M. K., Wainscoat, J. S., Johnson, P. J., Chang, A. M. Z., & Hjelm, N. M. (1998) · The American Journal of Human Genetics · doi:10.1086/301800 · Cited by 1,653
Rapid Clearance of Fetal DNA from Maternal Plasma
Lo, Y. M. D., Zhang, J., Leung, T. N., Lau, T. K., Chang, A. M. Z., & Hjelm, N. M. (1999) · The American Journal of Human Genetics · doi:10.1086/302205 · Cited by 1,157
Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer
Sozzi, G., Conte, D., Leon, M., Cirincione, R., Roz, L., Ratcliffe, C., Roz, E., Cirenei, N., Bellomi, M., Pelosi, G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.006 · Cited by 552
Progress and Challenges in Screening for Early Detection of Ovarian Cancer
Jacobs, I. J., & Menon, U. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r400006-mcp200 · Cited by 458
Zhong, X. Y., Laivuori, H., Livingston, J. C., Ylikorkala, O., Sibai, B. M., Holzgreve, W., & Hahn, S. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.109594 · Cited by 284
Self-citationMalkasian, G. D., Knapp, R. C., Lavin, P. T., Zurawski, V. R., Podratz, K. C., Stanhope, C. R., Mortel, R., Berek, J. S., Bast, R. C., & Ritts, R. E. (1988) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(88)80081-4 · Cited by 227
Quantitative Analysis of Circulating Mitochondrial DNA in Plasma
Chiu, R. W. K., Chan, L. Y. S., Lam, N. Y. L., Tsui, N. B. Y., Ng, E. K. O., Rainer, T. H., & Lo, Y. M. D. (2003) · Clinical Chemistry · doi:10.1373/49.5.719 · Cited by 208
Fetal DNA in maternal plasma is elevated in pregnancies with aneuploid fetuses
Yan Zhong, X., B�rk, M. R., Troeger, C., Jackson, L. R., Holzgreve, W., & Hahn, S. (2000) · Prenatal Diagnosis · doi:10.1002/1097-0223(200010)20:10<795::aid-pd897>3.0.co;2-p · Cited by 181 · cited 1×
“Control 36 53 21–78 Benign epithelial ovarian tumor 24 58 22–93 Epithelial ovarian cancer 21 61 32–90 Borderline tumor 8 (38) 50 32–74 Invasive carcinoma 13 (62) 68 34–90 Early stage 4 (19) 76 54–90 Advanced stage 9 (42) 64 34–85 Serous 15 (71) 64 32–90 Mucinous 6 (29) 53 34–85 CA 125 less than 35 U/mL 8 (38) 53 32–79…”
Self-citationLuthra, R., McBride, J. A., Cabanillas, F., & Sarris, A. H. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65546-0 · Cited by 119
Mehra, N., Penning, M., Maas, J., van Daal, N., Giles, R. H., & Voest, E. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1087 · Cited by 115 · cited 1×
“Although Mehra et al (2007) showed an elevated plasma mitochondrial DNA level in patients with advanced prostate cancer,12 Elliger et al (2008) could not find any significance between benign and malignant prostate lesions in terms of serum circulating cell-free mitochondrial DNA.13 However, levels…”
BackgroundClark, R. D., & Webster-Clark, D. J. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-008-9181-z · Cited by 112
Role of Cell‐Free Plasma DNA as a Diagnostic Marker for Prostate Cancer
Allen, D. J., Butt, A., Cahill, D. J., Wheeler, M., Popert, R., & Swaminathan, R. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1318.013 · Cited by 99
Amount of DNA in plasma and cancer risk: A prospective study
Gormally, E., Hainaut, P., Caboux, E., Airoldi, L., Autrup, H., Malaveille, C., Dunning, A., Garte, S., Matullo, G., Overvad, K., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20327 · Cited by 93
Quantification of Circulating DNA in the Plasma and Serum of Cancer Patients
Taback, B., O'Day, S. J., & Hoon, D. S. �. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1318.004 · Cited by 91
Elevated level of cell-free plasma DNA is associated with breast cancer
Zhong, X. Y., Ladewig, A., Schmid, S. M., Wight, E., Hahn, S., & Holzgreve, W. (2007) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-007-0345-1 · Cited by 82
Self-citationJacobs, I. J., & Oram, D. (1988) · PubMed · Cited by 81
ROSENTHAL, A. N., MENON, U., & JACOBS, I. J. (2006) · Clinical Obstetrics and Gynecology · doi:10.1097/00003081-200609000-00004 · Cited by 81
Zhong, S., Ng, M. C. Y., Lo, Y. M. D., Chan, J. C. N., & Johnson, P. J. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.6.466 · Cited by 59
Zhong, X. Y., Hahn, S., Kiefer, V., & Holzgreve, W. (2006) · Annals of Hematology · doi:10.1007/s00277-006-0182-5 · Cited by 55
Self-citationLevels of Circulating Cell-Free Serum DNA in Benign and Malignant Breast Lesions
Zanetti-Dällenbach, R. A., Schmid, S., Wight, E., Holzgreve, W., Ladewig, A., Hahn, S., & Zhong, X. Y. (2007) · The International Journal of Biological Markers · doi:10.1177/172460080702200202 · Cited by 38
Self-citationPre-operative prediction of serum CA125 level in women with ovarian masses.
Benjapibal, M., & Neungton, C. (2007) · PubMed · Cited by 27
Cited by
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
The Roles of Mitochondrial Damage-Associated Molecular Patterns in Diseases
Nakahira, K., Hisata, S., & Choi, A. M. K. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6407 · Cited by 360
“While the levels of circulating mtDNA are elevated in the patients with urological cancers (39, 98) and ovarian cancer (174), the levels of mtDNA are not increased in patients with Ewing sarcoma (173) or breast cancer (77).”
BackgroundCytoplasmic DNA: sources, sensing, and role in aging and disease
Miller, K. N., Victorelli, S. G., Salmonowicz, H., Dasgupta, N., Liu, T., Passos, J. F., & Adams, P. D. (2021) · Cell · doi:10.1016/j.cell.2021.09.034 · Cited by 288
Quantifying circulating cell-free DNA in humans
Meddeb, R., Dache, Z. A. A., Thezenas, S., Otandault, A., Tanos, R., Pastor, B., Sanchez, C., Azzi, J., Tousch, G., Azan, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41593-4 · Cited by 240
The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients
Elshimali, Y., Khaddour, H., Sarkissyan, M., Wu, Y., & Vadgama, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918925 · Cited by 236
“A significant difference between the epithelial ovarian cancer and endometriosis group was found in circulating cell-free mitochondrial DNA but not in circulating cell-free nuclear DNA [46].”
Background
Metadata
- Authors
- Zachariah, R. R., Schmid, S., Buerki, N., Radpour, R., Holzgreve, W., & Zhong, X.
- Affiliations
- University of Basel (CH)
- Venue
- Obstetrics & Gynecology
- Published
- 2008-10
- Volume
- 112
- Issue
- 4
- Pages
- 843-850
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2076316408
- Cited by
- 142
- References
- 25
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 5 · 2023: 7 · 2022: 5 · 2021: 18 · 2020: 8 · 2019: 12 · 2018: 8 · 2017: 10 · 2016: 6 · 2015: 6 · 2014: 7 · 2013: 8 · 2012: 11
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Obstetrics and Gynecology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- cell-free DNA, cell-free mitochondrial DNA, epithelial ovarian cancer, benign ovarian tumors, endometriosis, liquid biopsy, tumor markers, CA125
- MeSH terms
- Adult, Cell-Free System, DNA, Mitochondrial, DNA, Neoplasm, Endometriosis, Female, Humans, Ovarian Neoplasms, ROC Curve, Biomarkers, Tumor, Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.